| Literature DB >> 34873431 |
Manuel B Braga-Neto1,2,3, Deiziane V S Costa4, Dulciene M M Queiroz5, Felipe S Maciel3, Michelle S de Oliveira3, Antônio B Viana-Junior3, Flávia A Santos6, Renata F C Leitao4, Gerly A C Brito4, Paulo R L Vasconcelos7, Lucia L B C Braga1,3.
Abstract
BACKGROUND AND AIMS: First-degree relatives of gastric cancer patients are at increased risk of developing gastric cancer. Increased oxidative stress, including lipid peroxidation, has been associated with gastric carcinogenesis. Whether first-degree relatives of gastric cancer patients have increased oxidative stress remains unknown. We aimed to compare oxidative stress in patients with gastric cancer, their first-degree relatives, and dyspeptic controls.Entities:
Mesh:
Year: 2021 PMID: 34873431 PMCID: PMC8643263 DOI: 10.1155/2021/6657434
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Clinical characteristics of the sample population.
| Characteristics | Gastric cancer ( | Dyspeptic controls ( | Relatives of gastric cancer ( |
|
|---|---|---|---|---|
| Age (yrs), mean | 61 | 48 | 47.5 | 0.00a |
| Gender, | ||||
| Male | 34 (68) | 13 (23.2) | 15 (30.6) | 0.392a |
| Female | 16 (32) | 43 (76.8) | 34 (69.4) | 0.00b |
| Alcohol use, | 28 (56) | 17 (30.3) | 11 (22.4) | 0.08a |
| Chronic smoking, | 29 (58) | 8 (14.2) | 0 | 0.00a |
| Education level | ||||
| < 9 years | 42 (84) | 15 (26.8) | 20 (40.8) | 0.000a |
| ≥ 9 years | 8 (16) | 41 (73.2) | 29 (59.2) | 0.153b |
| Income | ||||
| < US$400 | 44 (88) | 40 (71) | 37 (75.5) | 0.036a |
| ≥ US$ 400 | 6 (12) | 16 (28.5) | 12 (24.4) | 0.597b |
| Lauren type | ||||
| Intestinal | 38 (76) | — | — | — |
| Diffuse | 12 (24) | — | — | — |
| TNM stage | ||||
| I | 12 (24) | — | — | — |
| II | 8 (16) | — | — | — |
| III | 6 (12) | — | — | — |
| IV | 24 (48) | — | — | — |
aControls vs. gastric cancer. bControls vs. relatives of gastric cancer.
Comparison of serum GSH concentration, CAT, MDA concentration, between controls and gastric cancer patients.
| Univariate | CG | GC |
|
|---|---|---|---|
| GSH | 337.76 (112.18-561) | 125.72 (46.29-220.41) | <0.001 |
| CAT | 0.97 (0.69-1.42) | 0.95 (0.43-1.33) | 0.355 |
| MDA | 3.85 (3.33-6.47) | 6.32 (3.94-12.13) | 0.011 |
| SOD | 0.66 (0.58-0.77) | 0.6 (0.48-0.73) | 0.163 |
| Multivariate∗ | CG | GC |
|
| GSH | 325.5 (309.25-380.42) | 137.84 (125.98-157.91) | <0.001 |
| CAT | 1.04 (0.92-1.15) | 0.9 (0.79-1.05) | 0.329 |
| MDA | 5.44 (5.16-5.57) | 8.93 (8.53-9.43) | 0.001 |
| SOD | 0.67 (0.67-0.68) | 0.6 (0.59-0.61) | 0.189 |
∗Values estimated for generalized linear model gama-log: intercept, sex, smoking, cancer, and age. Data presented as median (25th percentile-75th percentile). CG control group and GC gastric cancer group.
Figure 1(a) Glutathione serum level (GSH) expressed in μmol/mL; (b) serum catalase activity (CAT) expressed nmol/min; (c) malondialdehyde serum level (MDA), expressed in nmol/mL; and (d) superoxide dismutase, expressed in nmol/mg of protein, of control patients, gastric cancer (GC), and relatives of gastric cancer patients. Detailed univariate and multivariate analysis with p values are available in Tables 2 and 4. ∗p < 0.05 compared to control; #p < 0.05 compared to relative of the GC group. §SOD activity in a subset of patients (control group, n = 31; gastric cancer group, n = 32; relatives gastric cancer, n = 49).
Comparison of serum GSH concentration, CAT activity, MDA, and SOD activity between control group and gastric cancer stage I, II and III, IV.
| Control | I e II | III e IV |
| |
|---|---|---|---|---|
| GSH | 337.76 (112.18-561) | 78.41 (24.77-233.35) | 140.41 (77.47-206.88) | <0.001a,b |
| CAT | 0.97 (0.69-1.42) | 1.11 (0.55-1.49) | 0.85 (0.37-1.3) | 0.381 |
| MDA | 3.85 (3.33-6.47) | 5.82 (3.14-12.51) | 6.58 (4.45-11.83) | 0.028b |
| SOD | 0.64 (0.54-0.81) | 0.55 (0.44–0.67) | 0.49 (0.47–0.66) | 0.254 |
a p < 0.05 GC stage I, II vs. control. bp < 0.005 GC stage III, IV vs. control.
Comparison of serum GSH concentration, CAT activity, MDA concentration, and SOD activity between controls and familial gastric cancer patients.
| Univariate | CG | Relatives of GC |
|
|---|---|---|---|
| GSH | 337.76 (112.18-561) | 225.12 (117.47-438.06) | 0.147 |
| CAT | 0.97 (0.69-1.42) | 2.71 (1.53-5.38) | <0.001 |
| MDA | 3.85 (3.33-6.47) | 5.37 (3.6-10.82) | 0.051 |
| SOD | 0.66 (0.58-0.77) | 1.04 (0.83-1.15) | <0.001 |
| Multivariate∗ | CG | Relatives of GC |
|
| GSH | 313.36 (312.45-373.49) | 256.29 (255.88-305.12) | 0.258 |
| CAT | 1.05 (0.97-1.1) | 3.81 (3.51-3.93) | <0.001 |
| MDA | 5.15 (4.93-5.79) | 7.95 (7.78-8.92) | 0.003 |
| SOD | 0.67 (0.67-0.68) | 1.04 (1-1.05) | <0.001 |
∗Values estimated for generalized linear model gama-log: intercept, sex, smoking, cancer, and age. Data presented as median (25th percentile-75th percentile). CG control group and relatives of gastric cancer.
Comparison of serum GSH concentration, CAT activity, MDA concentration, and SOD activity and between gastric cancer patients and familial gastric cancer patients.
| Univariate | Relatives of GC | GC |
|
|---|---|---|---|
| GSH | 225.12 (117.47-438.06) | 125.72 (46.29-220.41) | 0.001 |
| CAT | 2.71 (1.53-5.38) | 0.95 (0.43-1.33) | <0.001 |
| MDA | 5.37 (3.6-10.82) | 6.32 (3.94-12.13) | 0.627 |
| SOD | 1.04 (0.83-1.15) | 0.6 (0.48-0.73) | <0.001 |
| Multivariate∗ | Relatives of GC | GC |
|
| GSH | 262.51 (255.84-275.57) | 144.64 (127.23-152.63) | 0.018 |
| CAT | 3.82 (3.47-4.05) | 0.91 (0.78-1.09) | <0.001 |
| MDA | 7.58 (7.25-9.12) | 9.25 (7.99-10.46) | 0.659 |
| SOD | 1.04 (1-1.05) | 0.6 (0.59-0.61) | <0.001 |
∗Values estimated for generalized linear model gama-log: intercept, sex, smoking, cancer, and age. Data presented as median (25th percentile-75th percentile). GC: gastric cancer.